Drugs & Pharmaceuticals

Medicare is running a pilot program capping the monthly cost of insulin, but there is no federal regulation in sight.

The "COVID era" is reteaching us a lesson that was learned in the 1990s and 2010s – that an effective direct-acting antiviral (DAA) medication can work wonders in controlling or eliminating a serious viral infection.

Putting aside the usual anti-pharma narrative for a moment, Merck, which is seeking emergency use authorizat

Atea Pharmaceuticals, which is (was?) co-developing another COVID antiviral drug with Roche called AT-527, issued a

Without a significant pull incentive, our pipeline of new antibacterials is doomed. This must be our top priority.

This year’s influenza (“flu”) season, which has already begun in some parts of the country, revs up in November, and last until spring, will be made more ominous than ever by the current high numbers of COVID-19 cases in many parts of the nation.&

As Professor Katherine Seley-Radtke (1) and I wrote last July in an op

Why are so many Americans unwilling to get a COVID-19 vaccine?

Remember back in the early days of COVID when we knew little about the disease and had nothing to treat it with? Remdesivir (brand name Veklury®) seemed promising for a while, but as I wrote last year:

The race to discover anti-COVID drugs, just like the race to discover any drugs, has been long (1) and frustrating.